Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01105702 · ClinicalTrials.gov registry record · Phase 2
Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma
A Phase 2 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT01105702 is a Phase 2 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 28 participants.
The verdict
NCT01105702, a Phase 2 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This pilot phase II trial studies how well giving temozolomide, bevacizumab, lithium carbonate, and radiation therapy works in treating patients with newly diagnosed high grade glioma.
Interventions
- DRUG Bevacizumab
- DRUG Temozolomide
- RADIATION Radiation
- DRUG Lithium Carbonate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2010-05 |
| Est. Completion | 2015-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01105702
The ClinicalTrials.gov registry entry for NCT01105702 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT01105702 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01105702 about?
NCT01105702 is a clinical study titled "Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma". This pilot phase II trial studies how well giving temozolomide, bevacizumab, lithium carbonate, and radiation therapy works in treating patients with newly diagnosed high grade glioma.
What is the current status of trial NCT01105702?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2010-05. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01105702?
The interventions under investigation include: Bevacizumab (DRUG), Temozolomide (DRUG), Radiation (RADIATION), Lithium Carbonate (DRUG).
Who is sponsoring clinical trial NCT01105702?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.